MGNX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MGNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Macrogenics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.13.
Macrogenics's long-term debt to total assets ratio increased from Dec. 2023 (0.10) to Dec. 2024 (0.13). It may suggest that Macrogenics is progressively becoming more dependent on debt to grow their business.
The historical data trend for Macrogenics's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Macrogenics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
LT-Debt-to-Total-Asset | Get a 7-Day Free Trial |
![]() |
![]() |
0.07 | 0.06 | 0.11 | 0.10 | 0.13 |
Macrogenics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
LT-Debt-to-Total-Asset | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.10 | 0.12 | 0.15 | 0.11 | 0.13 |
Macrogenics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as
LT Debt to Total Assets (A: Dec. 2024 ) | = | Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 ) | / | Total Assets (A: Dec. 2024 ) |
= | 32.597 | / | 261.655 | |
= | 0.12 |
Macrogenics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as
LT Debt to Total Assets (Q: Dec. 2024 ) | = | Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 ) | / | Total Assets (Q: Dec. 2024 ) |
= | 32.597 | / | 261.655 | |
= | 0.12 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Macrogenics (NAS:MGNX) LT-Debt-to-Total-Asset Explanation
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
Thank you for viewing the detailed overview of Macrogenics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey Stuart Peters | officer: Acting General Counsel | 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
James Karrels | officer: SVP, CFO and Secretary | 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Thomas Spitznagel | officer: Sr VP, BPD & Manufacturing | 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Eric Blasius Risser | officer: Sr VP & Chief Business Officer | 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Ezio Bonvini | officer: Sr VP, Research & CSO | 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Biotech Target N V | 10 percent owner | ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000 |
Edward Hurwitz | director | |
Margaret Liu | director | C/O SANGAMO, POINT RICHMOND TECH CNTR II, 501 CANAL BLVD, SUITE A-100, RICHMOND CA 94804 |
Meenu Chhabra | director | C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103 |
William K Heiden | director | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Biotech Ag Bb | 10 percent owner | SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200 |
Federica F. O'brien | director | C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355 |
Kenneth Galbraith | director | OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1 |
Stephen L. Eck | officer: Chief Medical Officer | 12212 TECHNOLOGY BLVD., AUSTIN TX 78727 |
Matthew K Fust | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
From GuruFocus
By Marketwired • 03-20-2025
By GuruFocus News • 02-15-2025
By Marketwired • 09-24-2024
By Marketwired • 11-05-2024
By GuruFocus News • 03-21-2025
By Business Wire • 09-24-2024
By GuruFocus News • 02-12-2025
By PRNewswire • 09-23-2024
By Marketwired • 02-27-2025
By GuruFocus News • 11-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.